Reuters logo
3 years ago
Cipla launches copy of GSK's top asthma drug in Germany, Sweden
September 1, 2014 / 1:29 PM / 3 years ago

Cipla launches copy of GSK's top asthma drug in Germany, Sweden

MUMBAI (Reuters) - India's Cipla Ltd (CIPL.NS) has launched an anti-asthma inhaler in Germany and Sweden that is a generic version of GlaxoSmithKline Plc's (GSK.L) Advair, a move that will further dent sales of the British firm's top-selling product.

Cipla's drug will be marketed under the name Serrofloin in Germany and Salmeterol/Fluticasone Cipla in Sweden, the Mumbai-based company said in a statement on Monday.

In December, Denmark became the first European country to approve for sale a generic version of GlaxoSmithKline's $8 billion (4.81 billion pounds)-a-year Advair, and analysts have been expecting more such approvals.

Making copies of inhaled drugs such as Advair is a challenge because of the complexity of making a device that effectively delivers the medicine directly into the lungs.

Reporting by Zeba Siddiqui in Mumbai; Editing by Prateek Chatterjee

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below